Skip to content

Xencor XNCR Total Equity

Total Equity at other companies

Amgen logo
AmgenAMGN
$9.19B+48.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Janux Therapeutics logo
Janux TherapeuticsJANX
$941.54M-7.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$938.08M-8.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.75M-62.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.34B+90.0%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's total equity?
Xencor (XNCR) reported total equity of $515.63M in Q1 2026.
How has Xencor's total equity changed year-over-year?
Xencor's total equity decreased by 19.4% year-over-year, from $639.87M to $515.63M.
What is the long-term trend for Xencor's total equity?
Over 5 years (2020 to 2025), Xencor's total equity has grown at a 2.1% compound annual growth rate (CAGR), from $572.44M to $635.59M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.